Reviva Pharmaceuticals
Cupertino
About Reviva Pharmaceuticals
Reviva Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burden to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory, and metabolic diseases. Reviva is using chemical genomics driven technology platform and proprietary chemistry to develop new medicines. Reviva’s pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $166.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:RVPH
- Website: revivapharma.com
- Phone: +114088161470
Industries & Categories
Biopharma, Biotechnology, Genetics, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/reviva-pharmaceuticals-155065 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.